Introduction
The prognosis of patients with Acute Myeloid Leukemia (AML) is predicted by conventional cytogenetics and gene (FLT3 status, which allow to stratify patients in groups with different probabilities to achieve and maintain complete remission (CR), providing the basis for riskoriented treatment. However, this information is not usually available at the time when induction chemotherapy is instituted; therefore risk-oriented treatment concerns post induction therapy, which is also conditioned by the results of bone marrow (BM) analysis and minimal residual disease (MRD) detection.
Quantification of MRD after induction cycle 5, 6 as well as during the course of post-remission therapy 7, 8 ,9 represents a powerful predictor of disease-free (DFS) and overall survival (OS). The Wilms' tumor gene 1 (WT1), which is overexpressed in more than 90% of AML, is an useful marker for monitoring MRD. The quantitative assessment of WT1 levels in BM after induction and consolidation therapy demonstrated high prognostic value irrespectively of cytogenetic or molecular abnormalities 10, 11, 12, 13 . Quantification of WT1 transcript level in peripheral blood (PB) leucocytes at recovery from chemotherapy reliably discriminated among patients at different risks of relapse 14 .
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The aim of our study was to determine whether assessment of changes of WT1 transcript levels in peripheral blood in the first days during induction therapy would provide information on the chemosensitivity of leukemic blasts and predict for clinically relevant end points.
Design and Methods

Patients
Eligibility criteria for entering the study were a diagnosis of non-M3 AML based on morphologic, cytochemical and immunophenotypical criteria and the presence of morphologically identifiable blast cells in PB. Only patients aged ! 65 were included in the study. The study was approved from local institutional review board, after written informed consent in accordance with Declaration of Helsinki.
Cytogenetic analysis was performed in BM cells at diagnosis according to the International System for human Cytogenetic Nomenclature 15 . Cytogenetic risk was assessed according to South West Oncology Group criteria 16 . Presence of FLT-3 internal tandem duplications (ITD) and NPM1 mutations were investigated as described 17, 18 . The definition of CR used established criteria 19 . DFS was measured from the date of CR achieved with the first cycle to relapse or last follow up. Overall survival (OS) was calculated from the diagnosis to the last observation or death; patients receiving allogeneic stem cell transplant (SCT)
were censored at the date of transplant.
All patients were treated with a "3+7" induction course: Cytarabine 100 mg/sqm over three hours intravenously infusion every 12 hours on days 1-7; Idarubicin 12 mg/sqm 30 min intravenous infused on days 1-3. High-dose Cytarabine (3 g/sqm bid days 1, 3, 5) was used as first consolidation cycle in patients attaining CR.
After the first induction course, patients with persistent disease (i.e. > 5% BM blasts at hematopoietic recovery) received a salvage regimen.
In an intention-to-treat approach, patients with high-risk cytogenetic, 
WT1 quantitative determination
Quantification of WT1 expression levels was performed in PB leukocytes collected on day 1 (immediately before starting therapy) and on day 5 (the fifth day after start of treatment, immediately before cytarabine infusion). This time was chosen based on the kinetics of PB blast disappearance during induction therapy determined with immunophenotyping 20, 21 . 
Results and Discussion
Between May 2004 and March 2007, 57 of 60 consecutive AML patients entering the study completed induction chemotherapy and were evaluable for response; their characteristics are shown in Table I . The median follow-up of the whole cohort of patients was 14 months (1-44).
CR was achieved after first cycle in 35 patients; of the 22 patients not achieving CR (NCR), 7 patients obtained partial remission while 15 patients were refractory.
Of the 35 patients achieving CR, 18 patients underwent autologous PBSCT, 3
patients received allogeneic SCT and 14 patients received consolidation chemotherapy.
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The median number of WT1 transcripts measured on day 1 (pre-treatment value) we calculated the "WT1 ratio" as the ratio of copy number measured on day 1 and on day 5; the median WT1 ratio for the whole patient population was 5.82
(0.54-327.71).
The median WT1 ratio was significantly greater in patients attaining CR (11.68 vs 2.14; p=0.0006). Of 28 patients with a WT1 ratio > 5.82 (i.e, the median value of the whole population) 23 (82.1%) achieved CR compared to 12 of 29 patients (41.4%) with a ratio ! 5.82 (p=0.002). These data suggested that WT1 ratio was predictive of CR attainment (Fig. 1A) . Furthermore, we found that among the 35 patients attaining CR after "3+7" course the DFS was significantly longer in those displaying a WT1 ratio > 5.82 (median 32.3 months) compared to those displaying a ratio ! 5.82 (median 13.8 months; p=0.024) (Fig. 1B) . Likewise, a WT1 ratio > 5.82 predicted for a significantly longer OS in all patients included in the study (median OS not reached) compared to patients with a ratio ! 5.82
(median OS 13.1 months; p<0.001) (Fig. 2) .
In a multivariate analysis including, age, white blood cells (WBC) count, karyotype and FLT3/NPM1 status, DFS was predicted by both WT1 ratio (p = 0.01) and WBC count (p=0.041), while WT1 ratio was the only variable predicting for the likelihood to achieving CR and for longer OS (p=0.009 and p=0.007, respectively). Furthermore, we performed a multi-variate analysis within patients attaining CR after the first induction cycle (n=35) including autologous transplant
in order to assess a possible impact of post-remission therapy on outcome.
Autologous transplantation did not demonstrate any impact on DFS and OS.
Overall, these data suggest that measurement of WT1 ratio after standard chemotherapy represents an important predictor of disease outcome.
Specifically, the kinetic of WT1 copies reduction correctly predicted the bone marrow response evaluated by standard morphologic criteria in the majority of cases. On the other hand, we noted that a subgroup of patients was wrongly predicted as being refractory on the basis of low WT1 ratios; however it is noteworthy that these patients showed a shorter DFS, that suggests poor quality of CR (Fig. 1A) .
The degree of WT1 copies reduction, expressed as WT1 ratio, rather than the absolute count of WT1 copies at day 5, provides an estimate of peripheral blasts clearance in each individual patient irrespectively of the baseline leukemic burden.
We used the median value of WT1 ratio measured in this patient population as a cut-off; as such, it should not be intended as an absolute value, and can also depend upon the type of treatment. The fact that measurement of WT1 ratio easily can be accomplished using PB samples anticipates the relevance of these findings for management of AML patients. In fact, an early outcome prediction might provide a tool to customizing therapeutic strategy since the first days of induction therapy. Patients with low reduction of WT1 have high probability of being refractory or early relapsing, and could be immediately switched to intensification of induction. On the other hand, patients with satisfactory WT1 reduction might continue standard induction protocol as this feature correlates with high rate of CR and longer DFS, avoiding unnecessary toxicity of an intensified induction.
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